ReviewCytoskeleton (Hoboken, N.J.)2025
Actin-Bundling Protein, Fascin-1, as a Target of Osteoarthritis Progression.
Review in Cytoskeleton (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The cellular mechanisms underlying osteoarthritis pathogenesis are not fully understood. However, recent in vivo and in vitro studies show that actin cytoskeletal reorganization plays a critical role in the progression of osteoarthritis. It has been shown that targeting the inhibition of actin-bundling protein, fascin, is a favorable way to reorganize actin and prevent chondrocyte dedifferentiation that occurs in osteoarthritis. In a surgical model of osteoarthritis, targeting fascin reduces cartilage degradation and disease severity. These findings highlight the therapeutic potential of targeting fascin in osteoarthritis. Future research to develop a further mechanistic understanding on the critical role actin and actin network molecules play in osteoarthritis may lead to the development of actin-based therapies against disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.